Calypso Biotech

Calypso Biotech is the third spin-off company from the EPP Fund. The company is developing antibody therapeutics against niche gastro-intestinal immune disorders, such as refractory celiac disease and Crohn`s Disease. Calypso Biotech is based in Geneva, Switzerland.

Team Members
more about
Cheryl Zimberlin
Investment Director
more about
Arnaud Autret
Investment Director
Latest News Entry
Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases

Dose-escalation study to evaluate safety, biological and early clinical effect of CALY-002 in healthy volunteers and patients with Celiac Disease and Eosinophilic Esophagitis

Calypso Biotech licenses CALY-001 best-in-class anti-MMP-9 antibody to EA Pharma

Calypso Biotech SA announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody.

all portfolio news